Hypothesis

Acarbose extends lifespan not only through metabolic improvement but also by eliciting low‑level gastrointestinal nociceptive signaling that acts as a hormetic stressor. The undigested starch that reaches the colon is fermented by microbiota, producing short‑chain fatty acids (SCFAs) and gaseous metabolites that cause luminal distension. This distension activates mechanosensitive and chemosensitive nociceptors (chiefly TRPV1 and Piezo2) on intestinal afferents, generating a mild, chronic pain signal. In males, androgen‑dependent up‑regulation of TRPV1 amplifies this signal, which then engages central stress‑response pathways (HSF1‑mediated heat‑shock response, Nrf2‑driven antioxidant gene expression, and enhanced autophagy) that improve proteostasis and delay aging. Consequently, suppressing this nociceptive input should blunt acarbose’s longevity effect without altering its metabolic or microbiome actions.

Testable Predictions

1. Pharmacological blockade of visceral nociception will reduce acarbose‑mediated lifespan extension. Male mice receiving acarbose plus a selective TRPV1 antagonist (e.g., capsazepine) or a Piezo2‑blocking peptide will show a significantly shorter survival than acarbose‑only controls, whereas female mice will exhibit a smaller or non‑significant change.
2. Nociceptive activation markers will rise with acarbose treatment. Acarbose‑fed mice will exhibit increased spinal cord phosphorylation of TRPV1 downstream effectors (p‑ERK, p‑CREB) and elevated colonic c‑Fos immunoreactivity compared with pair‑fed controls; these increases will be blunted by co‑administration of the antagonist.
3. SCFA production and metabolic improvements will remain intact when nociception is blocked. Plasma butyrate, acetate, propionate levels, insulin tolerance, and hepatic mTORC2/FOXO1a signaling will be indistinguishable between acarbose‑only and acarbose + antagonist groups, confirming that the longevity effect is dissociable from metabolic benefits.
4. Genetic reduction of visceral nociceptor function will phenocopy the pharmacological blockade. Mice lacking TRPV1 specifically in vagal afferents (Advillin‑Cre; Trpv1^fl/fl) will fail to obtain the full lifespan extension from acarbose, again with a stronger effect in males.

Experimental Design (brief)

• Cohorts: Male and female C57BL/6J mice, 4 months old, n=30 per group.
• Groups: (1) Control diet; (2) Acarbose (200 ppm); (3) Acarbose + TRPV1 antagonist (capsazepine 10 mg/kg i.p., thrice weekly); (4) Acarbose + vehicle.
• Endpoints: Survival monitoring (primary), colonic SCFA quantification (GC‑MS), plasma glucose/insulin tolerance tests, hepatic mTORC2 activity (p‑AKT‑S473), nociceptive signaling (colonic c‑Fos, spinal p‑ERK), and autophagy markers (LC3‑II/I, p62) in liver and muscle.
• Statistical analysis: Cox proportional hazards model for survival; two‑way ANOVA for biochemical endpoints with sex and treatment as factors.

Potential Outcomes and Interpretation

If the hypothesis is correct, groups receiving acarbose plus nociceptive blockade will show a significant reduction in median lifespan (e.g., from +22% to +5% in males) while retaining the SCFA‑mediated metabolic improvements. A lack of effect would falsify the notion that mild nociceptive signaling contributes to acarbose’s longevity action, supporting the view that its benefits are purely metabolic/microbiomal. Conversely, an extension of lifespan in females only when nociception is intact would underscore a sex‑specific hormetic component.

Broader Implications

Confirming that a low‑grade pain signal mediates part of acarbose’s effect would reframe gastrointestinal discomfort not as a side‑effect to be eliminated but as a potential biomarker of hormetic engagement. It would also suggest that combining mild microbiota‑targeted interventions with controlled nocceptive activation could be a strategy to harness longevity pathways without caloric restriction.

References

• Acarbose lifespan and microbiome: https://pubmed.ncbi.nlm.nih.gov/24245565/
• Hepatic mTORC2/FOXO1a: https://pubmed.ncbi.nlm.nih.gov/28834262/
• SCFA‑producing taxa correlation: https://www.gethealthspan.com/research/article/acarbose-glucose-control-gut-health-metabolic-disease-microbiome-aging
• Cancer‑prone mouse survival: https://lsom.uthscsa.edu/molecular-medicine/2020/02/20/acarbose-improved-survival-for-apc-min-mice/
• TRPV1 mediates CR‑induced longevity: https://pubmed.ncbi.nlm.nih.gov/25417144/
• SCFAs activate TRPV1: https://pubmed.ncbi.nlm.nih.gov/31534199/
• Visceral pain and TRPV1 in males: https://pubmed.ncbi.nlm.nih.gov/29563312/